CD274 and cancer: Recent preclinical and clinical studies have demonstrated that checkpoint blockade using anti‐CTLA‐4, anti‐PD‐1, and anti‐PD‐L1 antibodies can be successful for cancer immunotherapy 17, 18, 19.